TRIS PHARMA UNVEILS EXPANSION OF STATE-OF-THE-ART RESEARCH FACILITY

Tris Pharma, a privately-owned, specialty pharmaceutical company, today unveiled a new, state-of-the-art research and manufacturing facility at a South Brunswick, New Jersey campus. These expanded capabilities are a result of the company’s success with its innovative drug delivery technologies.

This 30,000- square-foot expansion adds a state-of-the-art, FDA-compliant cGMP facility and marks the transition of Tris Pharma to a technology firm that has all the capabilities including manufacturing, in one facility. The company can provide its partners clinical supplies, submission batches, eCTD filing, and medium-scale commercial production of tablets, capsules, liquid suspensions, and oral solutions, and packaging for the finished products.

"This facility enhances our manufacturing capabilities and also enables us to continue to invest in our drug development,” says Ketan Mehta, CEO and founder of Tris Pharma. “This is the final piece of the puzzle for our first phase of growth and keeps our operations scalable to keep pace with several more deals and new technologies in the pipeline."

Tris Pharma envisioned a cutting-edge manufacturing facility—and set out to build it. Rather than rely on outside contractors, the company hired top experts in the field to design and build the plant from scratch. The result is 15 cGMP suites that are completely flexible, with end-to-end in-built utilities and features that streamline the drug production process. The new facility also expands the company’s current capabilities by including a commercial- size vault for DEA controlled substances with manufacturing license of Schedules I to IV.

"The relationship between Interpharm and Tris Pharma has been an important partnership for the development of our joint products,” says Cameron Reid, CEO of Interpharm. “As we move toward commercialization, Tris will bring their manufacturing capability to the table for our liquid products".

About Tris Pharma:

Tris Pharma is a privately owned, product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms where by patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 30 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey. For more information visit http://www.trispharma.com

SOURCE Tris Pharma